Current status and prospect of treatments for recurrent hepatocellular carcinoma

Table 3 Overall survival and recurrence-free survival after ablation therapy for recurrent hepatocellular carcinoma

Ref.	Type	Years	n	1-, 3-, and 5-yr OS	1-, 3-, and 5-yr RFS
Sun et al[172]	Retrospective	2002-2014	57	98%/77%/53%	61%/27%/17%
Ho et al[103]	Retrospective	2001-2007	54	-/-/83%	N/A
Liang et al[182]	Retrospective	1999-2007	66	77%/49%/40%	N/A
Song et al[173]	Retrospective	1994-2012	178	99%/83% 71%	70%/41%/30%
Zhang et al[183]	Retrospective	2007-2014	50	100%/64%/64%	N/A
Feng et al[184]	Retrospective	2006-2016	199	91%/69%/56%	57%/28%/15%
Chan et al[93]	Retrospective	2001-2008	45	84%/43%/29%	32%/12%/9%
Koh et al[185]	Retrospective	2002-2011	42	-/-/24%	N/A
Chen et al[186]	Retrospective	2009-2015	57	78%/41%/37%	70%/38%/33%
Lu et al[81]	Retrospective	2004-2015	194	94%/75%/62%	N/A
Wang et al[104]	Retrospective	2004-2010	162	97%/73%/37%	90%/54%/27%

OS: Overall survival; RFS: Recurrence-free survival; HCC: Hepatocellular carcinoma; N/A: Not applicable.